Head-to-head · WeighScore
Fitstry vs Wellorithm
The verdict
Fitstry takes it — 61.5/100 to 48.5/100.
Fitstry grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Fitstry is the GLP-1 weight-loss program of Weightstry, LLC, a LegitScript-certified, cash-pay telehealth practice focused on women 40+.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Fitstry | Wellorithm |
|---|---|---|
| WeighScore | 61.5/100 | 48.5/100 |
| Grade | C | C |
| Scorecard rank | #292 | #486 |
| Semaglutide | $179/mo (annual plan, plus a separate fee, compounded) | Pricing not published |
| Tirzepatide | $269/mo (annual plan, compounded) | Pricing not published |
| Coverage | Coverage not published | 49 states (not Louisiana) |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Yes | Yes |
Graded #292 · C
Strengths
- Transparent pricing before you commit — compounded semaglutide from $179/mo, tirzepatide from $269/mo, oral GLP-1 from $209/mo (annual plan)
- Free screening with a one-time $99 program fee that is fully refunded if a clinician can't prescribe ('Approved, or Your $99 Back')
- Monthly price bundles a lab panel (CMP, A1c, lipids, TSH), unlimited clinician access, bi-weekly care coaching and a 24/7 Care Line
- Runs under Weightstry, LLC, a LegitScript-certified practice with an independently verifiable seal, a named support email and phone
- Full compounded lineup — weekly injection, daily oral tablet and microdosing options
Where it loses points
- Month-to-month pricing is notably higher than the annual plan ($249 vs $179 semaglutide, $339 vs $269 tirzepatide)
- Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
- Framed for women 40+, and serves 49 states rather than all 50 (the excluded state isn't disclosed publicly)
- Works with state-licensed compounding pharmacies but doesn't name a specific pharmacy partner on the Fitstry page
- Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Graded #486 · C
Strengths
- Both molecules in BOTH routes — compounded semaglutide and tirzepatide as injections and as oral dissolving tablets
- Four branded pens on the same account: Mounjaro, Ozempic, Wegovy and Zepbound
- Sermorelin offered alongside the GLP-1 line
- 24/7 phone support on a published number
Where it loses points
- No price appears anywhere on the public site — /pricing 404s and every product CTA leads to a 2-minute intake quiz, so no cost can be compared before signing up
- The site contradicts itself on coverage: the homepage says "Serving All 50 States" while its own FAQ says 49 states and excludes Louisiana
- The four clinicians presented as "board-certified obesity specialists" are listed as Cardiac Surgery, Pediatric Clinic, Gynecology and Cardiac Surgery — none in obesity medicine
- "100% Customer Satisfaction" is stated as a headline fact and is not a substantiable claim
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.